Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

PHASE3CompletedINTERVENTIONAL
Enrollment

793

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions
Clostridium Difficile InfectionInfectionCommunicable Diseases
Interventions
DRUG

RBX2660

RBX2660 is a microbiota suspension administered as an enema

Trial Locations (51)

10016

New York, New York

14618

Rochester, Rochester

15213

Pittsburgh, Pittsburgh

19107

Philadelphia, Philadelphia

19610

Wyomissing, Wyomissing

21215

Baltimore, Baltimore

22003

Annandale, Annandale

22150

Springfield, Springfield

27710

Durham, Durham

29425

Charleston, Charleston

30033

Decatur, Decatur

30309

Atlanta, Atlanta

32127

Port Orange, Port Orange

32224

Jacksonville, Jacksonville

32610

Gainesville, Gainesville

32806

Orlando, Orlando

34102

Naples, Naples

37212

Nashville, Nashville

37434

Hixon, Hixon

44195

Cleveland, Cleveland

46845

Fort Wayne, Fort Wayne

48202

Detroit, Detroit

53215

Milwaukee, Milwaukee

53704

Madison, Madison

54449

Marshfield, Marshfield

55446

Plymouth, Plymouth

55905

Rochester, Rochester

58122

Fargo, Fargo

60035

Gurnee, Gurnee

60527

Burr Ridge, Burr Ridge

63110

St. Louis, St Louis

67214

Wichita, Wichita

70121

New Orleans, New Orleans

71105

Shreveport, Shreveport

72117

North Little Rock, North Little Rock

73102

Oklahoma City, Oklahoma City

75246

Dallas, Dallas

77030

Houston, Houston

80045

Aurora, Aurora

83404

Idaho Falls, Idaho Falls

84088

West Jordan, West Jordan

85054

Phoenix, Phoenix

93030

Oxnard, Oxnard

98104

Seattle, Seattle

99202

Spokane, Spokane

06518

Hamden, Hamden

T2N 2T9

Calgary, Calgary

T6G 2X8

Edmonton, Edmonton

V5Z 1M9

Vancouver, Vancouver

V8R 1J8

Victoria, Victoria

E1C 6Z8

Moncton, Moncton

All Listed Sponsors
lead

Rebiotix Inc.

INDUSTRY

NCT03931941 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) | Biotech Hunter | Biotech Hunter